{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"The length of time from the participant's first complete response or partial response as assessed by RECIST Version 1.1 Criteria until disease progression or death. This outcome measure applies to all participants.","groups":[{"description":"SBT6050 plus trastuzumab deruxtecan\n\nSBT6050: Dosed with 0.45 mg/kg by subcutaneous (SC) injection in 21-day cycles\n\ntrastuzumab deruxtecan: 6.4 mg/kg by IV infusion in 21-day cycles","id":"OG000","title":"SBT6050 + T-DXd (6.4 mg/kg)"},{"description":"SBT6050 plus tucatinib and trastuzumab\n\nSBT6050: Dosed with 0.45 mg/kg by subcutaneous (SC) injection in 21-day cycles\n\ntucatinib: 300 mg by mouth (PO) twice daily (BID)\n\ntrastuzumab: 8 mg/kg loading dose (first dose), then 6 mg/kg maintenance dose (subsequent doses) IV infusion in 21-day cycles","id":"OG001","title":"SBT6050 + Tucatinib + Trastuzumab"}],"populationDescription":"Data not captured; study was terminated by Sponsor.","reportingStatus":"POSTED","timeFrame":"0 weeks","title":"Duration of Response for Participants With an Objective Response Rate","type":"SECONDARY"}